

**GOVERNMENT OF INDIA
HEALTH AND FAMILY WELFARE
LOK SABHA**

UNSTARRED QUESTION NO:6892
ANSWERED ON:11.05.2005
MARKETING OF GABAPENTIN
Acharia Shri Basudeb

Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

- (a) whether Government is aware that M/s Pfizer INC have paid \$430 million in fines and settled charges for flouting law for promotion and marketing of Gabapentin in case of Neuropathic pain without approval for such induction in the United States;
- (b) whether the Drug Control General of India, Mumbai, permitted M/s Sun Pharmaceuticals Industries Limited for promotion and marketing of Gabapentin in case of neuropain in India;
- (c) if so, the details thereof;
- (d) whether such sales promotion and marketing are in violation of drugs and cosmetic Act, 1940; and
- (e) if so, the action taken/ proposed to be taken in this regard?

Answer

THE MINISTER OF STATE IN THE MINISTRY OF HEALTH & FAMILY WELFARE (SMT. PANABAKA LAKSHMI)

- (a) This Ministry has no information that M/s. Pfizer Inc have paid \$ 430 million in fines and settle charge for flouting law for promotion and marketing of Gabapentin in case of Neuropathic pain without approval of such induction in United States.
- (b) & (c) M/s. Sun Pharma informed that the drug Gabapentin (Brand name - GABANTIN) is being only promoted for its approved indication for the treatment in epilepsy i.e. for the adjunctive therapy in the treatment of partial seizures with or without secondary generalization in adults with epilepsy.
- (d) & (e) Does not arise, in view of above.